pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
NOVARTIS · news · pharmadog
← back to NOVARTIS
News mentioning NOVARTIS
367
stories
22d
Q3 layoffs down YOY, with 90% fewer biopharma employees affected
biospace
22d
Argenx digests phase 2 celiac win for $2.2B drug, preps pivotal run
fiercebiotech
23d
Halozyme prevails in patent fight with Merck; Enliven readies anticipated leukemia trial
biopharma dive
23d
Novartis-partnered biotech nabs $150M Series B to move into the clinic
endpoints
23d
Doudna’s CAR T biotech Caribou to end R&D activities, slash staff as financing freezes up
biospace
23d
TCGX launches $600M fund to bankroll Asian biotechs
fiercebiotech
23d
Genmab and AbbVie’s Epkinly win, a rush of deals, Sarepta’s turnaround hopes, more
biospace
23d
Matchpoint nets $150M series B to take covalent med into clinic
fiercebiotech
23d
5 biggest venture capital raises of Q3 2026
biospace
24d
Compliance concerns hinder rollout of AI in drug manufacturing: Survey
biospace
25d
Trio of scientists who developed neuron light switches win Nobel Prize in Physiology or Medicine
fiercebiotech
25d
Weighing the risks of CAR T in autoimmune disease as Kyverna nears market
biospace
25d
Weighing the risks of CAR T in autoimmune disease as Kyverna nears market
biospace
28d
Novartis wagers almost $8B on a Chinese biotech’s RNA drugs
biopharma dive
28d
STAT+: Lilly bypasses Australian pharmacies with DTC model
stat
28d
STAT+: Pharmalittle: We’re reading about the 340B drug pilot program, an obesity drug disappointment, and more
stat
28d
Novartis bets up to $7.8B for an mRNA-encoded T cell engager from China’s Abogen
biospace
28d
Novartis takes rights to Abogen's mRNA T cell engager for $575M upfront
endpoints
28d
Novartis pens $7.8B deal for Abogen's in vivo autoimmune T-cell engager
fiercebiotech
29d
Mistrust in science and a juicy gene-editing lawsuit
stat
29d
Chutes & Ladders—Bayer taps new chief medical officer; Cantor appointed PhRMA CEO
fiercebiotech
Sep 30, 26
FDA starts review of Roche’s multiple sclerosis pill
biopharma dive
Sep 29, 26
Highlight Therapeutics illuminates positive ph. 2 topline data in high-risk skin cancer
fiercebiotech
Sep 29, 26
Biopharma recruiters see ‘signs of recovery’ as layoffs remain cool in Q3’26
fiercebiotech
Sep 29, 26
3 steps for taking on Novartis in radiopharma: Curium up first
biospace
Sep 28, 26
ai3Bio emerging from stealth to ‘take the gun out of the hands of the immune system’
fiercebiotech
Sep 28, 26
An ‘off-the-shelf’ CAR-T therapy from Adicet shows promise against lupus
biopharma dive
Sep 28, 26
FDA nod for Mirum’s Atebrioz makes 3 options for ultra-rare bone disease
biospace
Sep 28, 26
6 immunology targets to sustain a mammoth I&I market
biospace
Sep 25, 26
Adicet Bio CAR-T sparks lupus remissions in early trial as ‘new era’ of autoimmune treatment approaches
fiercebiotech
← prev
page 3 of 13
next →
